Trial results show setrusumab reduces the incidence of fracture and increases bone density and formation. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...

For decades, the rare bone condition osteogenesis imperfecta has been diagnosed on a spectrum, from mild to lethal. New research by Nemours Children's Health physicians suggests that many babies whose ...

NextCure, Inc. has presented new preclinical data at the Brittle Bone Society Meeting showing that its novel anti-Siglec-15 antibody, NC605, significantly improves bone microarchitecture and reduces ...

NOVATO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare ...

Mereo and Ultragenyx are collaborating to develop setrusumab, a sclerostin inhibitor, for treating patients with Osteogenesis Imperfecta. ASTEROID Phase 2 trial showed that setrusumab improved bone ...

Add Yahoo as a preferred source to see more of our stories on Google. Maybe you heard about it after watching the Samuel L. Jackson movie "Unbreakable." Or maybe after binging Season 11 of "Grey's ...

Please provide your email address to receive an email when new articles are posted on . The classification system associated with prenatally diagnosed osteogenesis imperfecta may be outdated. Modern ...

NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies ...

WESTLAKE VILLAGE, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for ...

A study conducted by researchers at Baylor College of Medicine and collaborating institutions reveals the molecular events leading to osteogenesis imperfecta type V, a form of brittle bone disease ...